The FDA recently approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis. Zinbryta is a long-acting subcutaneous injection that is administered once a month. Zinbryta has shown efficacy in two large clinical trials, one of which compared this drug to Avonex. There are additional safety concerns with this medication, however, including possible damage to the liver. Patients on Zinbryta will have to perform blood tests to monitor liver function...
more- Services
- Team
- Patient Education
- Diagnosing MS
- Understanding Some Basics About MS
- Relapsing Remitting MS
- Secondary Progressive MS
- Primary Progressive MS
- Preparing for Your New Patient Visit
- Preparing for a Spinal Tap
- Injection & Medication Counseling
- Relapse vs. Pseudorelapse
- Neuromyelitis Optics vs. Multiple Sclerosis
- Resources
- FAQ
- Research
- News
- Contact
- Leave a Review